TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SSY Group ( (HK:2005) ) has issued an announcement.
SSY Group Limited has announced that its antibiotic, Morinidazole, has received registration approval from China’s National Medical Products Administration. This development allows the drug to be marketed as a bulk drug for treating appendicitis and pelvic inflammatory disease caused by anaerobic bacteria, potentially enhancing the company’s market position and offering new opportunities for growth.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of medical products. The company specializes in antibiotics and other pharmaceutical preparations, targeting markets that require effective treatment solutions for bacterial infections.
Average Trading Volume: 14,439,585
Technical Sentiment Signal: Sell
Current Market Cap: HK$9.09B
Learn more about 2005 stock on TipRanks’ Stock Analysis page.